Literature DB >> 30645198

Multiple sclerosis - the remarkable story of a baffling disease.

Tomasz Grzegorski1, Jacek Losy1.   

Abstract

Multiple sclerosis has always been an enigma to its sufferers, their families, medical investigators, and clinicians. For many centuries, there have been attempts to understand its causes and nature, and to discover treatment methods. In the Middle Ages, the disease was claimed to be sent directly from God. A significant development in exploring multiple sclerosis took place in the 19th century, when Jean-Martin Charcot and his colleagues distinguished the disease, precisely described its symptoms, attempted to explain its pathophysiology, and introduced the first methods of symptomatic treatment. The 20th century was a period of discovery and development of diagnostic techniques, such as cerebrospinal fluid analysis, evoked potentials, and magnetic resonance imaging as well as an era of introducing steroid therapy for acute treatment. Currently, the dynamic development of disease modifying therapy and neuroimaging can be observed. The paper aims to delve into the remarkable history of multiple sclerosis by focusing on the earliest case reports and discovery of the disease and exploring its nature, diagnostic methods, and treatment.

Entities:  

Keywords:  Charcot; Lidwina of Schiedam; Salpêtrière; history; treatment

Mesh:

Substances:

Year:  2019        PMID: 30645198     DOI: 10.1515/revneuro-2018-0074

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  3 in total

1.  [Inflammatory diseases of the central nervous system].

Authors:  Armin Bachhuber
Journal:  Radiologe       Date:  2021-06-08       Impact factor: 0.635

2.  Translational Block in Stroke: A Constructive and "Out-of-the-Box" Reappraisal.

Authors:  Athanasios Lourbopoulos; Iordanis Mourouzis; Christodoulos Xinaris; Nefeli Zerva; Konstantinos Filippakis; Angelos Pavlopoulos; Constantinos Pantos
Journal:  Front Neurosci       Date:  2021-05-14       Impact factor: 4.677

Review 3.  Alzheimer's disease drug development pipeline: 2022.

Authors:  Jeffrey Cummings; Garam Lee; Pouyan Nahed; Mina Esmail Zadeh Nojoo Kambar; Kate Zhong; Jorge Fonseca; Kazem Taghva
Journal:  Alzheimers Dement (N Y)       Date:  2022-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.